Last updated 19 days ago

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

1150 patients around the world

Available in Puerto Rico, Chile, Argentina, United States

Akero Therapeutics, Inc

1150Patients around the world

This study is for people with

Fatty liver/nash

Nonalcoholic steatohepatitis

Steatohepatitis

Metabolic dysfunction-associated steatohepatitis - MASH

Cirrhosis

Compensated cirrhosis

To 80 Years

All Gender

: Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH.
Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH.

: Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results.
Type 1 diabetes or unstable Type 2 diabetes.
Any current or prior history of decompensated liver disease.

SponsorAkero Therapeutics, Inc

Study typeInterventional

Conditions

Nonalcoholic steatohepatitisMetabolic dysfunction-associated steatohepatitis - MASHCompensated cirrhosis

Requirements

To 80 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06528314